<DOC>
	<DOCNO>NCT00144521</DOCNO>
	<brief_summary>The purpose study investigate clinical efficacy safety MRA double-blind , parallel-group , control study use MRA methotrexate ( MTX ) rheumatoid arthritis ( RA ) patient MTX administer .</brief_summary>
	<brief_title>Comparative Study ( Double-Blind ) MRA Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion Diagnosis RA base 1987 classification criterion American College Rheumatology ( ACR ) Disease duration 6 month Treated 8 mg/week MTX least 8 week immediately precede enrollment , continue treatment initiation study drug Active disease enrollment ( le 2 week initiate treatment study drug ) , Which define least 6 tender 6 swollen joint among 49 46 joint stipulate Japanese Rheumatism Foundation 's Drug Evaluation Committee ESR least 30 mm/hr CRP le 1.0 mg/dL Exclusion criterion Assessed Class IV Steinbrocker functional activity 4 week precede treatment study drug Treated infliximab , etanercept leflunomide 12 week precede treatment study drug Received follow therapy 2 week precede initiation treatment study drug . 1 . Administration DMARD immunosuppressant MTX 2 . Administration corticosteroids exceed 10 mg/day prednisolone 3 . Dose escalation initiation corticosteroid Received follow therapy 4 week precede treatment study drug 1 . Plasma exchange therapy 2 . Surgical treatment ( operation , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>